NYSE:PEN - Penumbra Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $314.50
  • Forecasted Upside: 12.55 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.49 (-0.18%)

This chart shows the closing price for PEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Penumbra Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PEN

Analyst Price Target is $314.50
▲ +12.55% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Penumbra in the last 3 months. The average price target is $314.50, with a high forecast of $335.00 and a low forecast of $270.00. The average price target represents a 12.55% upside from the last price of $279.42.

This chart shows the closing price for PEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Penumbra. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/8/2021Wells Fargo & CompanyReiterated RatingBuyMedium
6/4/2021BTIG ResearchUpgradeNeutral ➝ Buy$291.00High
5/5/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target$325.00 ➝ $335.00Low
5/5/2021CitigroupBoost Price Target$325.00 ➝ $335.00High
5/5/2021Wells Fargo & CompanyBoost Price TargetOverweight$310.00 ➝ $321.00High
5/5/2021Canaccord GenuityBoost Price TargetBuy$310.00 ➝ $335.00High
2/24/2021CitigroupBoost Price TargetBuy$255.00 ➝ $325.00Low
2/24/2021Canaccord GenuityBoost Price TargetBuy$204.00 ➝ $310.00Medium
2/24/2021Wells Fargo & CompanyBoost Price TargetOverweight$260.00 ➝ $310.00Low
12/16/2020Wells Fargo & CompanyLower Price TargetOverweight$265.00 ➝ $215.00Medium
12/16/2020Canaccord GenuityLower Price TargetBuy$292.00 ➝ $204.00Medium
12/16/2020BTIG ResearchDowngradeBuy ➝ NeutralN/A
10/29/2020Smith Barney CitigroupBoost Price Target$264.00 ➝ $270.00Medium
10/29/2020Wells Fargo & CompanyBoost Price TargetOverweight$255.00 ➝ $265.00Low
10/29/2020Canaccord GenuityBoost Price TargetBuy$253.00 ➝ $292.00High
10/29/2020BTIG ResearchBoost Price TargetBuy$233.00 ➝ $259.00High
10/7/2020Canaccord GenuityReiterated RatingBuy$253.00High
9/29/2020BTIG ResearchInitiated CoverageBuy$233.00Low
9/8/2020Bank of AmericaDowngradeBuy ➝ NeutralMedium
8/4/2020Canaccord GenuityBoost Price TargetBuy$200.00 ➝ $245.00Medium
8/4/2020Wells Fargo & CompanyBoost Price TargetOverweight$205.00 ➝ $255.00Medium
8/4/2020CitigroupBoost Price TargetBuy$214.00 ➝ $264.00Medium
5/8/2020JPMorgan Chase & Co.Boost Price TargetOverweight$175.00 ➝ $200.00Low
5/8/2020CitigroupBoost Price TargetBuy$192.00 ➝ $214.00High
4/7/2020Canaccord GenuityReiterated RatingBuy$186.00 ➝ $184.00High
3/30/2020Wells Fargo & CompanyLower Price TargetOverweight$195.00 ➝ $180.00Medium
3/27/2020CitigroupLower Price TargetBuy$200.00 ➝ $192.00Low
3/4/2020CitigroupInitiated CoverageBuy$200.00Low
12/4/2019JPMorgan Chase & Co.Boost Price TargetOverweight$185.00 ➝ $200.00Medium
12/4/2019Canaccord GenuityReiterated RatingBuy$175.00 ➝ $200.00Medium
12/2/2019Royal Bank of CanadaReiterated RatingOutperform$192.00Low
8/7/2019Royal Bank of CanadaSet Price TargetBuy$174.00Low
8/1/2019Wells Fargo & CompanyBoost Price TargetOutperform$180.00 ➝ $185.00Low
6/13/2019Bank of AmericaBoost Price TargetBuy$150.00 ➝ $180.00Low
5/30/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$140.00 ➝ $170.00High
5/21/2019William BlairInitiated CoverageOutperformMedium
4/17/2019HC WainwrightReiterated RatingBuyHigh
1/30/2019Canaccord GenuityBoost Price TargetBuy$138.00 ➝ $160.00High
11/6/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$150.00 ➝ $152.00High
10/29/2018Bank of AmericaReiterated RatingBuy ➝ Buy$36.00Low
10/8/2018Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$174.00Low
8/20/2018Canaccord GenuityReiterated RatingBuy$175.00Low
8/9/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$140.00 ➝ $150.00Medium
5/31/2018Wells Fargo & CompanyReiterated RatingOutperform ➝ Outperform$150.00 ➝ $180.00Medium
5/9/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$115.00 ➝ $140.00High
5/9/2018Canaccord GenuityBoost Price TargetBuy$125.00 ➝ $165.00High
4/5/2018Canaccord GenuityReiterated RatingBuy$125.00Low
4/4/2018The Goldman Sachs GroupInitiated CoverageBuy$145.00High
3/13/2018Wells Fargo & CompanyBoost Price TargetReduce ➝ Outperform$138.00Medium
2/28/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$110.00 ➝ $115.00Low
2/28/2018Wells Fargo & CompanyBoost Price TargetOutperform ➝ Outperform$120.00 ➝ $125.00High
2/28/2018Canaccord GenuityReiterated RatingBuy ➝ Buy$113.00 ➝ $125.00High
2/21/2018William BlairInitiated CoverageOutperform ➝ OutperformLow
1/24/2018Canaccord GenuityReiterated RatingBuy$113.00Medium
1/2/2018JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralHigh
12/12/2017BMO Capital MarketsDowngradeOutperform ➝ Market Perform$117.00 ➝ $110.00High
11/8/2017Canaccord GenuityBoost Price TargetBuy$100.00 ➝ $113.00N/A
11/8/2017BMO Capital MarketsBoost Price TargetOutperform$96.00 ➝ $117.00N/A
10/13/2017BMO Capital MarketsReiterated RatingBuy$96.00N/A
8/9/2017Canaccord GenuityReiterated RatingBuy$94.00 ➝ $100.00High
6/16/2017BMO Capital MarketsReiterated RatingBuy$96.00Low
6/13/2017Canaccord GenuityReiterated RatingBuy$94.00High
5/10/2017BMO Capital MarketsReiterated RatingBuy$96.00High
4/11/2017BMO Capital MarketsReiterated RatingBuy$86.00Medium
3/27/2017Canaccord GenuityReiterated RatingBuy$91.00Low
10/17/2016BMO Capital MarketsInitiated CoverageOutperform$86.00N/A
7/20/2016Canaccord GenuitySet Price TargetBuy$67.00N/A
(Data available from 6/24/2016 forward)
Penumbra logo
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; immersive virtual reality and display system that displays and tracks upper-extremity rehabilitation exercises under the REAL Immersive System brand name; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand name, as well as a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and POD Packing Coil brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was founded in 2004 and is headquartered in Alameda, California.
Read More

Today's Range

Now: $279.42
Low: $279.13
High: $285.87

50 Day Range

MA: $271.63
Low: $235.00
High: $310.70

52 Week Range

Now: $279.42
Low: $163.49
High: $320.00


136,689 shs

Average Volume

376,091 shs

Market Capitalization

$10.19 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Penumbra?

The following Wall Street research analysts have issued research reports on Penumbra in the last twelve months: Bank of America Co., BTIG Research, Canaccord Genuity, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Smith Barney Citigroup, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for PEN.

What is the current price target for Penumbra?

6 Wall Street analysts have set twelve-month price targets for Penumbra in the last year. Their average twelve-month price target is $314.50, suggesting a possible upside of 12.4%. Canaccord Genuity has the highest price target set, predicting PEN will reach $335.00 in the next twelve months. Smith Barney Citigroup has the lowest price target set, forecasting a price of $270.00 for Penumbra in the next year.
View the latest price targets for PEN.

What is the current consensus analyst rating for Penumbra?

Penumbra currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PEN will outperform the market and that investors should add to their positions of Penumbra.
View the latest ratings for PEN.

What other companies compete with Penumbra?

How do I contact Penumbra's investor relations team?

Penumbra's physical mailing address is One Penumbra Place, Alameda CA, 94502. The company's listed phone number is (510) 748-3200 and its investor relations email address is [email protected] The official website for Penumbra is www.penumbrainc.com.